WASHINGTON — A House panel passed a bipartisan bill to ban drug middlemen from charging fees based on drug list prices — the first in Congress’ raft of PBM reform efforts that would actually ban the practice in at least some of the employer-sponsored insurance market.
The bill, by Rep. Mariannette Miller-Meeks (R-Iowa), would only allow PBMs to charge a flat service fee, separating those fees from list prices. The bill also would ban the PBM practice, called spread pricing, of charging insurers more than they pay pharmacies. And it would prohibit PBMs from steering patients to pharmacies affiliated with them.
Those changes would only apply to health insurance for federal employees. The Federal Employees Health Benefits program covers more than 8 million of the nearly 160 million Americans who are covered by health insurance from their employer.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect